Are Oral Dissolving Strips FDA Approved? ODF Regulation

Approved, registered, cleared: what the words mean

The question buyers ask most is whether oral dissolving strips are FDA approved. For a dietary supplement strip, the answer is no, and it is no for every dietary supplement in every dosage form. FDA states plainly: "By statute, the FDA does not approve dietary supplements for safety and effectiveness." The agency adds that "many dietary supplements can be marketed without even notifying the FDA."

FDA also does not approve manufacturing facilities on their own. In the agency's words, "the agency does not approve manufacturing facilities independently," and registration "does not denote approval of the establishment." So the phrase FDA registered means only that a facility has filed the registration required of food facilities that manufacture, process, pack, or hold food (including dietary supplements) for consumption in the United States, a registration that must be renewed every other year under the Food Safety Modernization Act. It is a filing, not a review.

A manufacturer that says its oral strips are FDA approved is either describing an approved drug product or contradicting FDA's own consumer guidance. The verify claims guide explains how to check registration; this guide explains the framework the product sits in. Nothing here is legal advice; classification, label review, and claims substantiation are decisions for the brand and its regulatory counsel.

Three pathways: supplement, OTC monograph drug, or new drug

An oral dissolving film is a dosage form, not a regulatory category. The same physical strip can be a dietary supplement, an over-the-counter drug, or a prescription drug depending on what is in it and what it is intended to do. Under 21 U.S.C. 321(g), a drug includes articles "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" and articles (other than food) "intended to affect the structure or any function of the body." Dietary supplements are carved out of the second prong by DSHEA so that structure/function claims can be made without drug status, but only if the product meets the dietary supplement definition.

For nonprescription drugs, FDA describes "two regulatory pathways for nonprescription drugs to come to market: the drug application process and the OTC drug monograph process." A monograph sets the permitted actives, strengths, indications, and labeling for a category; a conforming product can be marketed without an application, but it is a drug, made under drug cGMP, and labeled with Drug Facts. A new active, dose, or indication needs a new drug application.

Decide the pathway first, because it determines the manufacturer you need, the quality system, the testing scope, the label format, and the claims you can make. StripWorks scopes oral films as dietary supplements and does not quote drug-pathway products as supplements; the restricted actives guide lists where that line most often gets crossed.

The DSHEA definition and the ingestion requirement

DSHEA (Public Law 103-417, enacted October 25, 1994) added the dietary supplement definition to the Federal Food, Drug, and Cosmetic Act at section 201(ff). A dietary supplement is "a product (other than tobacco) intended to supplement the diet" that contains one or more dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, "a dietary substance for use by man to supplement the diet by increasing the total dietary intake," or a concentrate, metabolite, constituent, extract, or combination of those.

The definition then adds form requirements. The product must be one that "is intended for ingestion" in a form such as a tablet, capsule, powder, softgel, gelcap, or liquid, or otherwise be intended for ingestion and not represented as a conventional food or the sole item of a meal; and it must be "labeled as a dietary supplement." FDA's summary is shorter: "A dietary supplement is a product intended for ingestion that, among other requirements, contains a 'dietary ingredient' intended to supplement the diet."

The definition also excludes articles approved as new drugs, or authorized for investigation as new drugs where substantial clinical investigations have been made public, unless the article was marketed as a supplement or food first. That drug-exclusion clause underlies FDA's positions on CBD and other ingredients covered in the restricted actives guide. For an oral film, the clause that matters most is the one about ingestion.

StripWorks' own pages describe products as oral dissolving films and avoid broad statements that a supplement strip bypasses digestion, is absorbed sublingually or has superior bioavailability unless the specific product has evidence and the regulatory classification supports the claim. Sublingual and buccal wording on a supplement label should be reviewed by regulatory counsel before publication.

Why sublingual and buccal absorption claims create drug-classification risk

An oral dissolving film dissolves in the mouth. Whether it is intended for ingestion or for absorption through the oral mucosa is a matter of labeling and marketing, and FDA has treated that distinction as decisive. In a February 5, 2019 warning letter on a sublingual melatonin product, FDA explained that dietary supplements must be intended for ingestion and that because the product was "intended to enter the body directly through the skin or mucosal tissues," it was not a dietary supplement and not a food. A May 18, 2021 warning letter on another sublingual product used the same reasoning: such products "are intended to enter the body directly through the skin or mucosal tissues" and fall outside the definition regardless of any other exclusion.

FDA's draft NDI guidance reinforces the point. It describes a dietary supplement as a product "which by definition is intended for ingestion," and lists a "different route of administration (e.g., an article that has a history of safe use in sublingual form and is now intended for ingestion as an NDI)" as a change that needs new safety support. The agency treats sublingual use and ingestion as different routes.

For an oral strip brand this is the single most important regulatory fact. A strip labeled as a dietary supplement that dissolves in the mouth and is swallowed is on the supplement side of the line. Copy that says the strip bypasses digestion, delivers the active into the bloodstream through the tissue under the tongue, or is for sublingual or buccal absorption describes a product not intended for ingestion, and FDA has treated such products as unapproved drugs. StripWorks frames supplement strips as dissolving in the mouth for ingestion and avoids absorption-route claims. Whether a particular label stays on the supplement side is a decision for the brand's regulatory counsel, made before the carton is printed.

21 CFR Part 111: cGMP for supplement manufacturers

Because FDA does not review supplements before sale, the law puts the burden on the firm. FDA states that "a firm is responsible for ensuring that the dietary supplements it manufactures or distributes are not adulterated, misbranded, or otherwise in violation of federal law" and that it must "follow current good manufacturing practices that help ensure the identity, purity, quality, strength, and composition" of the product. Those practices are codified at 21 CFR Part 111, which applies to anyone who manufactures, packages, labels, or holds a dietary supplement.

Part 111's subparts map directly to what a buyer should ask an oral film manufacturer about: personnel (B); physical plant (C); equipment (D); the production and process control system (E); quality control (F); components, packaging, and labels (G); the master manufacturing record (H); the batch production record (I); laboratory operations (J); manufacturing operations (K); packaging and labeling operations (L); holding and distributing (M); returned product (N); product complaints (O); and records (P).

The words that matter in a quote are specification, master manufacturing record, batch record, and release. Under Part 111 the manufacturer must set specifications for components and finished product, verify they are met (21 CFR 111.75 requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient), document each batch against the master record, and have quality control approve the batch before release. Ask an oral film manufacturer how each of those functions is performed for your product, and confirm the scope in writing. This guide describes the regulation; it makes no claim about StripWorks' own certifications or registrations, which are confirmed in project documentation rather than on a web page.

New dietary ingredients and the 75-day notification

A dietary ingredient that was not marketed in the United States before October 15, 1994 is a new dietary ingredient (NDI). Under 21 CFR 190.6, "at least 75 days before introducing or delivering for introduction into interstate commerce a dietary supplement that contains a new dietary ingredient" that has not been present in the food supply in an unaltered form, "the manufacturer or distributor of that supplement, or of the new dietary ingredient, shall submit" to FDA the information on which it has concluded the supplement "will reasonably be expected to be safe." FDA's consumer Q&A states the same 75-day rule and notes it is the main exception to the principle that supplements can be marketed without notifying the agency.

An NDI notification is not an approval. FDA reviews it and responds, and publishes a list of submitted notifications, but a response letter that raises no objection is not a finding that the ingredient is safe or that another firm can rely on it. The draft NDI guidance discusses when a notification is required and how a change in dose, duration, or route of administration affects the safety evidence needed.

For an oral film, the NDI question comes up three ways. Novel or trend-driven actives (many longevity, nootropic, and peptide-adjacent ingredients) may be NDIs with no notification on file. If the brand's marketing implies a different route, the ingestion issue above returns. And the obligation belongs to the manufacturer or distributor, so a brand cannot assume its contract manufacturer has handled it. Ask in writing whether each active's NDI status is resolved, and confirm with regulatory counsel.

Structure/function claims and the disclaimer

DSHEA lets supplement labels carry structure/function claims: statements that "describe the role of a nutrient or dietary ingredient intended to affect the normal structure or function of the human body," such as calcium builds strong bones. FDA requires that "the manufacturer must have substantiation that the claim is truthful and not misleading and must submit a notification with the text of the claim to FDA no later than 30 days after marketing" the product. The claim may not state or imply that the product diagnoses, treats, cures, or prevents a disease; as FDA puts it, "only a drug can legally make such a claim."

The disclaimer is fixed text. Under 21 CFR 101.93(c), a label with one such statement must say: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." With more than one statement, the plural form ("These statements have not been evaluated...") may be used. The disclaimer must be placed adjacent to the claim or linked to it with a symbol, and the notification and disclaimer requirements apply to dietary supplements, not to conventional foods.

For oral strips the claims that most often cross the line are delivery claims: faster absorption, higher bioavailability, bypasses the digestive system. Those read as absorption-route claims (the ingestion problem) and as implied superiority claims needing substantiation. The safer framing describes what the product is (a dissolving strip taken by mouth) and the ingredient's role in the diet, with the disclaimer, and leaves absorption physiology off the label. Confirm claim language with regulatory counsel before print.

Labeling basics under 21 CFR Part 101

FDA's Dietary Supplement Labeling Guide lists five statements every supplement label must carry: a statement of identity (the name of the product, identifying it as a dietary supplement), the net quantity of contents, nutrition labeling in the Supplement Facts format, an ingredient list, and the name and place of business of the manufacturer, packer, or distributor. The guide states that "you must place the statement of identity and the net quantity of contents statement on the principal display panel," and the Supplement Facts panel, ingredient list, and name and place of business on the information panel.

The Supplement Facts panel is governed by 21 CFR 101.36, which requires that "the label of a dietary supplement that is offered for sale shall bear nutrition labeling in accordance with this regulation" and specifies the serving size line, dietary ingredients and amounts per serving, percent Daily Value where one exists, and other ingredients. For a strip, serving size is expressed in strips and net quantity in strips per package, which makes the 20-count versus 30-count decision a labeling decision as well as a commercial one.

Two oral-film specifics deserve attention. Individual sachets are labeling too; if a sachet leaves the carton, plan the information consumers will see across carton and sachet. And the disclaimer, serving size, the address or phone number for adverse event reports, and lot and expiration coding all have to fit on a small package, so label layout should start before the dieline is final. Label review with regulatory counsel belongs on the critical path, not after artwork approval.

StripWorks reviews manufacturing and packaging requirements for the agreed product and market. The brand owner remains responsible for its specific retail-channel and state-by-state commercial requirements unless those services are expressly included in the project.

Serious adverse event reporting

The Dietary Supplement and Nonprescription Drug Consumer Protection Act added a mandatory reporting duty. FDA's guidance states: "The manufacturer, packer, or distributor whose name (pursuant to section 403(e)(1) of the FD&C Act) appears on the label of a dietary supplement marketed in the United States is required to submit to FDA all serious adverse event reports associated with use of the dietary supplement in the United States." Reports "must be submitted to FDA no later than 15 business days after the report is received by the responsible person," as must follow-up reports received within one year. The report is filed on MedWatch Form FDA 3500A or its electronic equivalent, and "the responsible person must maintain all records related to each report of a serious adverse event for a period of 6 years."

The responsible person is whoever's name is on the label. For a private-label oral strip that is the brand, not the contract manufacturer. The brand therefore needs a process for receiving consumer reports through the address or phone number on the label, evaluating whether an event is serious, filing within the deadline, and keeping records.

Set this up before launch: a monitored contact channel, a written procedure, and an agreement with the manufacturer on how complaints and adverse events are shared, since Part 111 separately requires the manufacturer to handle product complaints (Subpart O). The quality agreement should say who does what.

Child-resistant packaging and other packaging considerations

Child-resistant packaging for supplements is a Consumer Product Safety Commission rule under the Poison Prevention Packaging Act, not an FDA rule, and it is narrow. Under 16 CFR 1700.14(a)(13), dietary supplements that contain the equivalent of 250 mg or more of elemental iron in a single package (above specified concentrations) must be in child-resistant packaging. Most oral strip formulas do not contain iron at that level, so the federal requirement usually does not apply.

That does not end the analysis. Strips are small, flavored, and often packed in sachets that can look like candy to a child, and retailers, marketplaces, and destination markets may set their own packaging expectations beyond the federal minimum. Whether to use a child-resistant carton or a tamper-evident sachet is a product decision to make with regulatory counsel and the channel in mind, not a box to tick on the federal list.

Two other packaging points are regulatory rather than cosmetic. The sachet and carton must carry the label information consumers need, and the package is part of the product's stability and shelf-life evidence under Part 111, since moisture is the main threat to an oral film. Packaging choices belong in the specification, the stability plan, and the label review, not just the artwork brief. The packaging guide covers the structural options.

Common questions

Primary sources

• FDA — Is It Really 'FDA Approved'?
• FDA — Questions and Answers on Dietary Supplements
• FDA — FDA 101: Dietary Supplements
• Public Law 103-417, Dietary Supplement Health and Education Act of 1994 (GovInfo, Statutes at Large)
• 21 U.S.C. 321 — definitions of 'drug' (g) and 'dietary supplement' (ff) (Office of the Law Revision Counsel)
• FDA — Over-the-Counter (OTC) Nonprescription Drugs
• FDA — Registration of Food Facilities and Other Submissions
• 21 CFR Part 111 — Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements (GovInfo, 2025 edition)
• 21 CFR Part 111 on eCFR (current text)
• FDA — New Dietary Ingredient (NDI) Notification Process
• 21 CFR 190.6 — Requirement for premarket notification (GovInfo)
• FDA — Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues (PDF)
• FDA Warning Letter — DK Vitamins (sublingual melatonin), February 5, 2019
• FDA Warning Letter — Umbrella (sublingual product), May 18, 2021
• FDA — Structure/Function Claims
• 21 CFR 101.93 — Certain types of statements for dietary supplements (GovInfo)
• FDA — Dietary Supplement Labeling Guide, Chapter I: General Dietary Supplement Labeling
• 21 CFR 101.36 — Nutrition labeling of dietary supplements (GovInfo)
• FDA — Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements
• 16 CFR 1700.14 — Substances requiring special (child-resistant) packaging (GovInfo)
• FDA — Premarket Tobacco Product Applications